Table 4 Clinical studies that investigating molecular features, MSI-H and CIMP-H in signet ring cell colorectal cancer

From: Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma

Study

n

Stage

Histology

KRAS (n, %)

NRAS (n, %)

BRAF (n, %)

PIK3CA (n, %)

FBXW7 (n, %)

APC (n, %)

TP53 (n, %)

SMAD4 (n, %)

MSI-H (n, %)

CIMP-H (n, %)

Present study

35

IV

Confirmed ≥ 50% SC

4/35 (11.4%)

0/35 (0.0%)

3/35 (8.6%)

1/35 (2.9%)

1/35 (2.9%)

1/35 (2.9%)

21/35 (60.0%)

5/35 (14.3%)

4/33 (12.1%)

1/3 (33.3%)

Kawabata Y, 199924

10

II–IV

Not confirmed

1/9 (11.0%)

–

–

–

–

–

–

–

3/10 (30.0%)

–

Kakar S, 20054

45

I–IV

Confirmed ≥ 50% SC

–

–

–

–

–

–

–

–

12/45 (26.7%)

–

Ogino S, 200625

9

NA

Confirmed ≥ 50% SC

0/8 (0.0%)

–

2/9 (22.0%)

–

–

–

–

–

2/8 (25.0%)

–

Kakar S, 201217

33

I–IV

Confirmed ≥ 50% SC

16/30 (53.3%)

–

9/27 (33.3%)

–

–

–

–

–

8/33 (24.2%)

16/33 (48.5%)

Hartman DJ, 201316

53

I–IV

Confirmed ≥ 50% SC

–

–

16/50 (32.0%)

–

–

–

–

–

23/53 (43.4%)

–

Inamura K, 201515

20

I–IV

Confirmed ≥ 50% SC

1/17 (5.9%)

–

6/17 (35.3%)

1/16 (6.2%)

–

–

–

–

5/17 (29.4%)

5/17 (29.4%)

Nitsche U, 201612

160

I–IV

Not confirmed

–

–

–

–

–

–

–

–

1/5 (20.0%)

–

Wei Q, 20167

39

I–IV

Confirmed ≥ 50% SC

5/33 (15.2%)

–

1/33 (3.0%)

–

–

–

–

–

–

–

Yalcin S, 201728

9

II–IV

Confirmed ≥ 50% SC

–

–

4/9 (36.4%)

–

–

–

–

–

–

–

Nam JY, 201827

5

NA

Confirmed > 50% SC

2/5 (40.0%)

0/5 (0.0%)

–

0/5 (0.0%)

1/5 (20.0%)

1/5 (20.0%)

2/5 (40.0%)

1/5 (20.0%)

–

–

Back to article page